ORAMED PHARMACEUTICALS INC.
For the period ended Dec 31, 2024. Filed Mar 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 27, 2025
ORMP$3.97-0.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Income (Loss)
| Year ended December 31, · Year ended December 31, | |||
|---|---|---|---|
| 2024 · 2023 | |||
| REVENUES | $ | - | $1,340 |
| RESEARCH AND DEVELOPMENT EXPENSES | (6,324) | (8,971) | |
| SALES AND MARKETING | - | 287 | |
| GENERAL AND ADMINISTRATIVE EXPENSES | (6,457) | (8,425) | |
| OPERATING LOSS | (12,781) | (15,769) | |
| INTEREST EXPENSES (note 11b) | (853) | (2,037) | |
| FINANCIAL INCOME (EXPENSES), NET (note 11a) | (2,286) | 22,894 | |
| INCOME (LOSS) BEFORE TAX EXPENSES | (15,920) | 5,088 | |
| TAX EXPENSES | (3,183) | - | |
| NET INCOME (LOSS) | $(19,103) | $5,088 | |
| NET INCOME (LOSS) ATTRIBUTABLE TO: | |||
| COMPANY’S STOCKHOLDERS | (19,060) | 5,525 | |
| NON-CONTROLLING INTERESTS | (43) | (437) | |
| NET INCOME (LOSS) | $(19,103) | $5,088 | |
| BASIC INCOME (LOSS) PER SHARE OF COMMON STOCK | $(0.48) | $0.14 | |
| DILUTED INCOME (LOSS) PER SHARE OF COMMON STOCK | $(0.48) | $0.14 | |
| WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING BASIC INCOME (LOSS) PER SHARE OF COMMON STOCK | 40,828,380 | 40,315,068 | |
| WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING DILUTED INCOME (LOSS) PER SHARE OF COMMON STOCK | 40,828,380 | 40,566,901 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.